EGFR VEDVsPNU+EDVs40 mer
Alternative Names: D682-carrying EDV™ - EnGeneIC; Designer EDVTM; E-EDV-D682; E-EDV-D682 - EnGeneIC; EGFR VEDVsPNU; EGFR-VEDVsPNU-EnGeneIC; PNU-159682Latest Information Update: 09 Jul 2025
At a glance
- Originator EnGeneIC
- Class Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Pancreatic cancer; Solid tumours
Most Recent Events
- 30 Jun 2025 Engeneic Pty plans a phase I/IIa Carolyn-USA trial for Pancreatic cancer(Combination therapy, Metastatic disease, Second-line therapy or greater) in USA(IV) in September 2025 (NCT07049055)
- 13 May 2025 Phase-I/II clinical trials in Solid tumours (Adjuvant therapy, Late-stage disease, Second-line therapy or greater) in Australia (IV) (ACTRN12625000203459)
- 07 Dec 2023 EGFR VEDVsPNU+EDVs40 mer receives Fast track status from the US FDA for Pancreatic cancer